Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568178927> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2568178927 endingPage "S1302" @default.
- W2568178927 startingPage "S1301" @default.
- W2568178927 abstract "Nivolumab is a human IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response- including the anti-tumor immune response. Due to the novelty of the mechanism of action and the limited treatment experience all checkpoint inhibitors can potentially induce treatment related AEs in any organ system that have not been noticed until now. The Syndrome of Inappopriate Antidiuresis (SIAD)-leading to hyponatremia with variant symptoms of CNS affection- is a frequent paraneoplastic syndrom in patients with advanced cancer, especially small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but can also be induced by a large number of anticancer drugs, however, not reported for Nivolumab until now. We report a 56year old heavily pretreated patient who was first diagnosed with squamous NSCLC in 2012. After symptomatic progression he started 4th line therapy on Nivolumab treatment (3mg/kg, q2w) in August 2015 after EMA licensing. After 3 months of treatment we noted disease stabilization with a radiographic minor response together with a slight improvement of tumor symptoms. Thus, therapy was continued. After 6 months treatment CT scan showed for the first time a partial response, however patient reported a clinical deterioration with onset of new symptoms (headache, dizziness, fatigue, nausea, blurred vision). Lab results showed severe hyponatremia (nadir 116mmol/l) caused by SIAD (serum osmolality 254 mOsm/kg), possibly induced by Nivolumab as other potential causes were excluded. No signs of intracranial progression or hypophysitis (brain MRI, CSF cytology, endocrinology lab) were detected. In the phase III registration trial the median time to response was 2.2 months. In our patient hyponatremia occurred in a timely relationship with partial response of the disease (after 6 months of treatment). After 2 months Tolvaptan treatment (an oral ADH antagonist) sodium levels normalized, accompanied by improvement of hyponatremia-symptoms. The patient is still in PR on Nivolumab treatment without treatment interruptions with normal sodium levels. We report a patient case (squamous NSCLC) where chemotherapy was not able to induce long lasting radiographic remissions or clinical benefit. After switching to Nivolumab therapy the patient achieved a partial remission after 6 month of continous Nivolumab with a simultaneous onset of hyponatremia. To the best of our knowledge, this is the first report of a Nivolumab response occuring simultaneously with SIAD. Therefore we speculate that hyponatremia might be a predictor for Nivolumab treatment response." @default.
- W2568178927 created "2017-01-13" @default.
- W2568178927 creator A5006360930 @default.
- W2568178927 creator A5049904099 @default.
- W2568178927 date "2017-01-01" @default.
- W2568178927 modified "2023-09-30" @default.
- W2568178927 title "P3.02c-044 Nivolumab-Response in a Patient with Advanced Squamous NSCLC Occurring Simultaneously with SIAD" @default.
- W2568178927 doi "https://doi.org/10.1016/j.jtho.2016.11.1839" @default.
- W2568178927 hasPublicationYear "2017" @default.
- W2568178927 type Work @default.
- W2568178927 sameAs 2568178927 @default.
- W2568178927 citedByCount "1" @default.
- W2568178927 countsByYear W25681789272017 @default.
- W2568178927 crossrefType "journal-article" @default.
- W2568178927 hasAuthorship W2568178927A5006360930 @default.
- W2568178927 hasAuthorship W2568178927A5049904099 @default.
- W2568178927 hasBestOaLocation W25681789271 @default.
- W2568178927 hasConcept C121608353 @default.
- W2568178927 hasConcept C126322002 @default.
- W2568178927 hasConcept C143998085 @default.
- W2568178927 hasConcept C203014093 @default.
- W2568178927 hasConcept C2776256026 @default.
- W2568178927 hasConcept C2776703092 @default.
- W2568178927 hasConcept C2777701055 @default.
- W2568178927 hasConcept C2780030458 @default.
- W2568178927 hasConcept C2780580376 @default.
- W2568178927 hasConcept C2780851360 @default.
- W2568178927 hasConcept C71924100 @default.
- W2568178927 hasConcept C8891405 @default.
- W2568178927 hasConceptScore W2568178927C121608353 @default.
- W2568178927 hasConceptScore W2568178927C126322002 @default.
- W2568178927 hasConceptScore W2568178927C143998085 @default.
- W2568178927 hasConceptScore W2568178927C203014093 @default.
- W2568178927 hasConceptScore W2568178927C2776256026 @default.
- W2568178927 hasConceptScore W2568178927C2776703092 @default.
- W2568178927 hasConceptScore W2568178927C2777701055 @default.
- W2568178927 hasConceptScore W2568178927C2780030458 @default.
- W2568178927 hasConceptScore W2568178927C2780580376 @default.
- W2568178927 hasConceptScore W2568178927C2780851360 @default.
- W2568178927 hasConceptScore W2568178927C71924100 @default.
- W2568178927 hasConceptScore W2568178927C8891405 @default.
- W2568178927 hasIssue "1" @default.
- W2568178927 hasLocation W25681789271 @default.
- W2568178927 hasOpenAccess W2568178927 @default.
- W2568178927 hasPrimaryLocation W25681789271 @default.
- W2568178927 hasRelatedWork W1183554201 @default.
- W2568178927 hasRelatedWork W2318567272 @default.
- W2568178927 hasRelatedWork W2544577077 @default.
- W2568178927 hasRelatedWork W2904759734 @default.
- W2568178927 hasRelatedWork W2972926806 @default.
- W2568178927 hasRelatedWork W3011519715 @default.
- W2568178927 hasRelatedWork W3029010559 @default.
- W2568178927 hasRelatedWork W3097428643 @default.
- W2568178927 hasRelatedWork W3215044659 @default.
- W2568178927 hasRelatedWork W4322754005 @default.
- W2568178927 hasVolume "12" @default.
- W2568178927 isParatext "false" @default.
- W2568178927 isRetracted "false" @default.
- W2568178927 magId "2568178927" @default.
- W2568178927 workType "article" @default.